Navigation Links
Dr Reddy’s Laboratories to challenge patents on drug

Pharma major Dr Reddy’s Laboratories will continue to aggressively challenge patents on drugs in the US despite the recent denial of a 180-day marketing exclusivity to its generic Omeprazole 40 mg capsules by the US Food and Drug Administration. Omeprazole is indicated for the treatment of duodenal and gastric ulcers.

The FDA granted the marketing exclusivity to Andrx group of the US. The loss of marketing exclusivity is a setback for Dr Reddy’s, but this will be temporary. This is to be expected in the game of patent challenges but since generic drugs provide an enormous opportunity, Dr Reddy’s Laboratories will continue to aggressively challenge the patents on other drugs.//

Apart from generic drug challenges, Dr Reddy’s Laboratories is also focusing on patent generic drugs, innovative drug deliveries and drugs which are difficult to formulate. Nothing can be as profitable as a generic drug, because of the manufacturing cost advantage. In fact, the marketing exclusivity on fluoxetine is the best thing to have happened to Dr Reddy’s in a very long time.

The next generic drug which Dr Reddy’s hopes to launch in the US is Ciprofloxacin, on which Bayer AG has a patent till December 2003. Other generic drugs in Dr Reddy’s pipeline are Olanzapine, on which Eli Lilly has a patent, and Ondansetron, on which Glaxo SmithKline Beecham has the patent, but these will be in 204.
'"/>




Page: 1

Related medicine news :

1. Dr Reddy’s Laboratories launches Hyalosy
2. Dr Reddy’s Strikes Deal With Rheoscience For Type 2 Diabetes Dru
3. Dr Reddy’s Laboratories launches Hyalosy
4. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
5. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
6. Abbott’s Laboratories R&D Capabilities Questione
7. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
8. ICMR to Set up Laboratories to Combat Bird Flu
9. Ranbaxy Laboratories to Be Aided in Drug Research
10. Bangladesh to Set Up HIV/AIDS Diagnosis Laboratories
11. Finding relief from Excruciating Headaches a challenge
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/25/2016)... ... ... CloudLIMS, joins an elite number of companies that have earned a spot on ... CIOReview. , In a deliberate session with the honorary industrial experts, a list of ... with. The positioning is based on evaluation of CloudLIMS’ specialties in Automated Sample Management ...
(Date:5/25/2016)... ... 25, 2016 , ... DKT International, one of the largest ... pleased to release their 2015 global impact data. In 2015, DKT served over ... deaths and 3.8 million unsafe abortions across 21 countries worldwide. , “We ...
(Date:5/25/2016)... Mexico (PRWEB) , ... May 25, 2016 , ... Casa ... the restorative properties of precious stones to complement its new wellness suites . ... two floors and feature a plethora of special services and insuite amenities, from a ...
(Date:5/25/2016)... ... ... more than fifty years, we've suffered whiplash as each new scientific study seemed to contradict ... nutritional advice – advice that was supposed to keep us healthy and slim. And what ... are considered to be overweight and more than 1 in 3 adults are considered to ...
(Date:5/25/2016)... ... 25, 2016 , ... Researchers from SUNY State College of Optometry won the ... visual evoked potential and human attention. The article, VEP and Human Attention: Translation ... ERG and VEP Vision Testing System (Diopsys, Inc., Pine Brook, NJ) to record ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)...   , Study met both ... in , Excellent plus Good ... of the ascending colon   ,      ... announced new positive data from the phase III MORA study for ... litre PEG with ascorbate. The study met both primary endpoints showing ...
(Date:5/24/2016)... 2016 ARANZ Medical  Ltd a ... sector, has been named the Coretex Hi-Tech Emerging Company of ... Dr Bruce Davey , CEO of ARANZ Medical ... really good to be recognised for the work we are ... used in 35 countries around the world from Sub-Saharan Africa ...
(Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
Breaking Medicine Technology: